German pharmaceutical company Stada Arzneimittel AG, known for its generics, consumer-health, and specialty drug portfolio, is preparing for a potential initial public offering (IPO) in autumn 2025, according to CEO Peter Goldschmidt. The move is part of the company’s broader strategy to strengthen its international footprint and capitalize on a robust pipeline of in-licensed products.
Since taking over as CEO in 2018, Goldschmidt has transformed Stada from a primarily Germany-focused generics supplier into a diversified, international healthcare player. The company now operates across three main divisions: Generics, Consumer Healthcare, and Specialty Pharma. This diversification has helped Stada deliver consistent growth, mitigate risks, and build a resilient revenue base.
Under Goldschmidt’s leadership, Stada has achieved strong financial performance. In the first half of 2025, adjusted EBITDA rose to €481 million, reflecting a 5% currency-adjusted increase. The generics segment contributed solid growth of 6%, while the specialty division, which includes biosimilars and niche therapies, surged by 25%. In 2024, Stada posted group sales of approximately €4.06 billion and an adjusted EBITDA of €886 million, demonstrating the company’s strengthened operational efficiency and strategic execution.
Goldschmidt has emphasized that the IPO is contingent on market conditions. Earlier plans for a spring 2025 listing were delayed due to market volatility, but now, with greater stability in capital markets, the company sees a renewed opportunity. Stada has also completed around 50 in-licensing deals in the first half of 2025, adding promising products to its portfolio and ensuring a strong pipeline for growth.
An IPO would mark a significant milestone for Stada, giving investors exposure to a mid-sized, growth-oriented European healthcare company rather than a traditional mega-cap pharmaceutical firm. Analysts note that the company’s balanced revenue mix, robust pipeline, and European market presence make it an attractive candidate for public investors seeking stable, long-term growth in the healthcare sector.
However, the IPO path is not without challenges. The company must manage its debt levels carefully, as leverage could limit strategic flexibility. Execution risk also remains, as not all in-licensed products may achieve expected returns. Regulatory risks in the generics space, including potential pricing pressures in key European markets, are additional factors to consider.
Beyond financial considerations, Stada’s IPO reflects the importance of leadership in corporate transformation. Goldschmidt’s tenure illustrates how a clear vision, strategic diversification, and disciplined execution can strengthen a company’s market position. For founders and entrepreneurs, the Stada story highlights key lessons: evolving beyond core markets, leveraging in-licensing to accelerate growth, and building a strong, governance-ready organization in preparation for a public listing.
The company’s strategy also demonstrates the growing significance of global footprint and operational agility. By balancing generics, specialty drugs, and consumer healthcare, Stada has positioned itself to absorb market volatility and capitalize on emerging opportunities across Europe and beyond. This approach can serve as a blueprint for mid-sized healthcare companies and startups seeking to scale internationally.
In conclusion, Stada Arzneimittel AG’s plans for a potential IPO under CEO Peter Goldschmidt showcase a company that has evolved strategically, financially, and operationally. With a diversified product portfolio, strong financial performance, and a robust pipeline of licensed products, Stada is well-positioned to enter public markets successfully. The IPO will not only provide capital for future growth but also signal the company’s maturity as a global healthcare player. For investors, entrepreneurs, and industry observers, Stada’s journey is a compelling example of how leadership, strategy, and execution combine to create market-ready organizations capable of thriving on an international stage.
